AstraZeneca's stock surges on FTSE 100 on Tagrisso approval

AstraZeneca’s (LON: AZN) stock surged on the FTSE 100 index following the announcement of the approval of its lung-cancer drug Tagrisso, in combination with chemotherapy. AstraZaneca’s shares were up by 3%, or 304.0 pence, reaching 10,398 pence. However, despite this recent rise, the stock has experienced a decline of 9.4% over the past year. Tagrisso approval boostsCopy link to sectionThe approval was granted based on promising trial results, demonstrating that Tagrisso combined with chemotherapy significa ...